

2Q 2022 Fact Sheet

Jeisys

Disclaimer

► it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to uncertainties, changes in the organizational structure, redefinition of accounting policies, etc., and may cause the actual results to differ from those stated or implied in this material.

I. P/L (K-IFRS)

Consolidated based on K-IFRS (Unit : KRW million)	2020					2021					2022				
	1Q	2Q	3Q	4Q	Accumulated	1Q	2Q	3Q	4Q	Accumulated	1Q	2Q	3Q	4Q	Accumulated
Sales	11,484	7,867	14,276	14,202	47,829	17,258	19,239	20,404	24,395	81,296	25,334	30,770			56,104
Cost of sales	3,569	2,831	3,149	4,541	14,090	4,712	5,913	6,026	7,998	24,649	7,638	10,056			17,694
Ratio(%)	31%	36%	22%	32%	29%	27%	31%	30%	33%	30%	30%	33%			32%
Gross profit	7,915	5,036	11,127	9,661	33,739	12,546	13,326	14,378	16,397	56,647	17,696	20,715			38,411
Ratio(%)	69%	64%	78%	68%	71%	73%	69%	70%	67%	70%	70%	67%			68%
SG&A	4,966	5,950	4,357	7,435	22,709	7,613	7,460	8,184	9,784	33,042	9,147	11,753			20,900
Operating profit	2,949	-914	6,770	2,226	11,030	4,933	5,865	6,194	6,613	23,604	8,549	8,962			17,510
Ratio(%)	26%	-12%	47%	16%	23%	29%	30%	30%	27%	29%	34%	29%			31%
Net profit before income tax	2,988	-2,767	6,525	1,468	8,215	-5,657	5,747	6,391	6,613	13,093	8,399	9,366			17,765
Net profit	2,434	-2,622	6,250	1,481	7,543	-6,303	5,634	6,135	8,026	13,493	6,512	7,360			13,873
Ratio(%)	21%	-33%	44%	10%	16%	-37%	29%	30%	33%	17%	26%	24%			25%
EBITDA	3,404	-236	7,312	2,880	13,254	5,507	6,413	6,859	7,245	26,024	9,257	9,704			18,961
Ratio(%)	30%	-3%	51%	20%	28%	32%	33%	34%	30%	32%	37%	32%			34%

Note1) 2021 1Q _ Other losses (Merger cost KRW 10,569million)

II. Sales by Item (K-IFRS)

Consolidated based on K-IFRS (Unit : KRW million)	2020					2021					2022				
	1Q	2Q	3Q	4Q	Accumulated	1Q	2Q	3Q	4Q	Accumulated	1Q	2Q	3Q	4Q	Accumulated
HIFU	2,036	2,918	2,207	3,036	10,198	3,304	3,466	3,601	2,645	13,015	3,628	3,062			6,690
RF	2,584	464	1,375	2,605	7,028	3,974	2,994	3,837	5,881	16,686	7,058	9,355			16,413
IPL	861	604	599	1,106	3,170	514	661	946	2,378	4,499	1,234	2,010			3,244
LASER	1,336	381	591	416	2,724	1,591	2,007	2,295	1,797	7,690	2,503	2,596			5,099
Consumables	4,011	2,738	8,602	6,557	21,907	7,260	9,413	9,573	11,069	37,315	10,237	13,120			23,357
Others	655	762	902	482	2,801	615	699	153	625	2,091	674	628			1,302
Total	11,484	7,867	14,276	14,202	47,829	17,258	19,239	20,404	24,395	81,296	25,334	30,770			56,104

III. Sales by Channel (K-IFRS)

Consolidated based on K-IFRS (Unit : KRW million)	2020					2021					2022				
	1Q	2Q	3Q	4Q	Accumulated	1Q	2Q	3Q	4Q	Accumulated	1Q	2Q	3Q	4Q	Accumulated
Domestic	2,208	1,792	2,644	2,567	9,211	2,459	2,848	3,093	3,743	12,144	3,433	3,894			7,327
Overseas	9,276	6,075	11,632	11,635	38,617	14,798	16,391	17,311	20,652	69,152	21,901	26,876			48,777
Total	11,484	7,867	14,276	14,202	47,829	17,258	19,239	20,404	24,395	81,296	25,334	30,770			56,104

IV. Major Device Sales

Total company (Unit : EA)	2020					2021					2022				
	1Q	2Q	3Q	4Q	Accumulated	1Q	2Q	3Q	4Q	Accumulated	1Q	2Q	3Q	4Q	Accumulated
ULTRACel Q+(LinearFirm)	120	175	126	146	567	164	196	212	171	743	238	186			424
Cumulative Sales	988	1,163	1,289	1,435	-	1,599	1,795	2,007	2,178	-	2,416	2,602			-
POTENZA	100	13	70	91	274	175	99	108	192	574	300	410			710
Cumulative Sales	287	300	370	461	-	636	735	843	1,035	-	1,335	1,745			-

V. B/S (K-IFRS)

Consolidated based on K-IFRS (Unit : KRW million)	2020					2021					2022				
	1Q	2Q	3Q	4Q	12/31	1Q	2Q	3Q	4Q	12/31	1Q	2Q	3Q	4Q	12/31
Current assets	21,816	20,097	26,984	28,264	28,264	41,060	39,180	46,012	54,173	54,173	61,487	67,776			
Cash and cash equivalents	7,759	9,533	17,047	17,591	17,591	19,582	23,263	28,668	34,291	34,291	36,394	32,274			
Short-term trade Receivable	5,145	3,041	2,562	3,338	3,338	5,945	5,144	5,183	6,872	6,872	8,198	11,000			
Inventories	6,993	5,888	5,653	5,766	5,766	6,190	8,171	9,679	10,578	10,578	13,234	18,329			
Non-current assets	8,797	10,368	10,153	10,903	10,903	10,829	11,316	12,468	19,886	19,886	23,692	27,686			
Total assets	30,613	30,465	37,136	39,167	39,167	51,889	50,496	58,481	74,059	74,059	85,178	95,462			
Current liabilities	23,901	10,429	10,668	12,918	12,918	12,957	14,799	14,548	24,027	24,027	24,757	29,097			
Non-current liabilities	13,217	16,669	11,157	9,290	9,290	9,936	8,678	8,569	2,379	2,379	4,040	3,995			
Total liabilities	37,118	27,098	21,825	22,208	22,208	22,893	23,477	23,117	26,405	26,405	28,797	33,092			
Issued capital	2,048	2,767	3,043	3,043	3,043	7,063	7,063	7,130	7,130	7,130	7,130	7,130			
Total equity	-6,505	3,367	15,312	16,959	16,959	28,996	27,020	35,364	47,654	47,654	56,381	62,370			

Jeisys Medical Inc.

Hang-In Lee (IR Team leader) / Mail : hilee@jeisys.com